Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer
Ning Li(Shenyang Pharmaceutical University), Lingying Wu(Chang Gung University), Jianqing Zhu, Yingjie Yang(Guilin Medical University), Shuzhong Yao(Sun Yat-sen University), Yi Huang(Hubei Cancer Hospital), Min Hao(Shanxi Medical University), Hong Zheng(The University of Texas MD Anderson Cancer Center), Pengpeng Qu(Tianjin Central Hospital of Gynecology Obstetrics), Dongling Zou(Chongqing Cancer Hospital), Beihua Kong(Qilu Hospital of Shandong University), Jianmei Hou, Ke Wang(Tianjin Medical University Cancer Institute and Hospital), Rutie Yin(Sichuan University), Juan Wang(Central South University), Jing Wang(Central South University), Jihong Liu(Sun Yat-sen University), Yu Zhang(Wannan Medical College), Chunyan Wang(Liaoning Cancer Hospital & Institute), Guiling Li(Union Hospital), Ge Lou(Harbin Medical University), Lin An, Hongying Yang(Kunming Medical University), Ziling Liu(Jilin University), Xiaohua Wu(Fudan University Shanghai Cancer Center), Weiguo Lü(Women's Hospital, School of Medicine, Zhejiang University), Xiaoa Zhen, Hongqin Zhao(Wenzhou Medical University), Hongbing Cai(Wuhan University), Lingya Pan(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenzhao Hang, Yueyin Pan(University of Science and Technology of China), Li Wang(China Three Gorges University), Heng Cui(Wuhan University)
Cited by 165
Related Papers
PARP inhibitor resistance: the underlying mechanisms and clinical implications
|Molecular Cancer|2020|527
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311